Company Overview
Vision and Mission
Leadership Team
Board of Directors
ESG
The United Nations Global Compact
Contact Us
Pipeline and Major Products
Discovery
Manufacturing
Partners
Press Releases
Media Coverage
Awards
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
Analyst Coverage
Corporate Governance
Events Calendar
IR Contact and Email Alert
Job Opportunities
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava™ for the Treatment of Complicated Intra-abdominal Infections
Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
Everest Medicines CEO Awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award
Everest Medicines Announces Amended Agreement with Spero Therapeutics
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
Everest Medicines Appoints Lan Kang to Board of Directors
Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy™ (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy™ (sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy™ for Metastatic Breast Cancer in China
Everest Medicines Announces the Offer Price and Allotment Results of the Global Offering
Everest Medicines Announced Its Global Offering and Proposed Listing on the Stock Exchange of Hong Kong
Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China
Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China